Revive Therapeutics Update Following U.S. FDA Approval of Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, Aug. 05, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV,…

Revive Therapeutics Announces Submission of Investigational New Drug Application (IND) with U.S. FDA for Phase 3 Confirmatory Study for Bucillamine in COVID-19

TORONTO, June 30, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV),…

Revive Therapeutics Expands Research Partnership for Novel Formulation Development and Clinical Research of Psilocybin with the University of Wisconsin-Madison

TORONTO, June 12, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV),…

A promising psychedelic company with a rich ip portfolio

Since December 2019, Revive Therapeutics| RVV (CSE) has seen a surge of more than 360% to…

RVV | A penny stock that may have an Influenza / Covid-19 treatment in its hands ?

For several weeks, the world has been upside down due to the rapid spread of a…

New coverage in cannabis pharma sector with over 1300% upside potential | Revive Therapeutics

Introducing New Featured Stock Pick : Revive Therapeutics Ltd. | RVV The Cannabis Stock is proud to…